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Objective: The objective of this study is to investigate the inﬂuence of the day-to-day variability of the measures
of heart rate variability (HRV) on the sample size calculation for the study of cardiac autonomic neuropathy.
Material andmethods:We analyzed HRV in the frequency domain [very low (VLF), low (LF), and high frequency
(HF) bands] and in the time domain [the root mean squared of successive RR intervals differences (RMSSD);
the mean RR intervals (RRNN); the standard deviation of RR intervals (SDNN) and the coefﬁcient of variation
(CV)] during a 5-min electrocardiogram record. We also analyzed the heart rate response to deep breathing
[expiration:inspiration ratio], to the Valsalva maneuver and to standing [maximum:minimum ratio] and the
blood pressure response to standing. The day-to-day variability was assessed by calculating the within-subject
standard deviations (WSSD), limits of agreement, typical errors and the ratio of the WSSD to the mean values
obtained on days 1 and 2 (WSSD/GM).
Results: Sixty-seven healthy subjects (45 females), aged 27 (19–39) years, were recruited. The RMSSD, CV, VLF, LF,
HF and blood pressure response to standing showedmarked variability (WSDD/GM(%) = 237.7, 455.1, 69.9, 126.5,
81.3 and 380.5, respectively), while the RRNN, SDNN, Valsalva, expiration:inspiration and maximum:minimum
ratio showed less variability (WSSD/GM (%) = 6.4, 24.5, 18.6, 11.0 and 14.1, respectively). The minimum differ-
ences expected to be statistically signiﬁcant for the autonomic measurements were calculated.
Conclusion: Some tests that assess HRV showed adequate reproducibility. This study allows the determination of a
sample size calculation for longitudinal or drug-testing studies.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular autonomic neuropathy (CAN) is one of the most
common chronic complications of diabetes mellitus and, despite its
signiﬁcant negative impact on survival and quality of life, is among
the least recognized and understood complication of the disease
(Rolim et al., 2008; Vinik et al., 2011).from Conselho Nacional de
il.
, Serviço de Diabetes, 3rd andar,
2128688224.
annus).
rights reserved.Clinical symptoms of CAN generally do not occur until long after the
onset of the disease, whichmakes the use of noninvasive electrocardio-
graphic tests critical for assessing the overall autonomic activity (Vinik
et al., 2003).
The prevalence of CAN ranges from 2.6% to 90% among personswith
diabetes, depending on the diabetes duration and themethodology and
diagnostic criteria used in various studies (Schmid, 2007).
However, because a patient's history and physical examination are
insufﬁcient for the early detection of CAN, tests for the evaluation of
heart rate variability (HRV), including the expiration to inspiration
ratio and the heart rate response to the Valsalva maneuver and stand-
ing, in addition to specialized tests based on components of the spectral
analysis of HRV, such as the beat-to-beat HRV and different bands of
spectral analysis [very low (VLF), low (LF) and high frequency (HF)
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cardiovascular autonomic system and to diagnose CAN (Boulton et al.,
2005).
The diagnosis of CAN is based onmaneuvers capable of investigating
the autonomic nervous system (ANS) activity of the heart. An abnor-
mality at any point in the reﬂex arc of the cardiovascular ANS can
alter end-organ function and can be inﬂuenced by many factors, such
as eating, obesity, drinking coffee, smoking, ethanol, exercise, stress,
fever, hypo- or hyperglycemia andmedications, such as aspirin, antihis-
tamines, nasal sprays,β-blockers and anti-arrhythmic agents (Dyck and
Thomas, 1999; Kowalewski and Urban, 2004).
The performance of cardiovascular reﬂex tests should be standard-
ized regarding the period of fasting, the number and type of tests
required for diagnosis, the duration of the test (spectral analysis of
short or long term), the reference values stratiﬁed for sex and age, the
differences in the statistical analysis tests (logarithmic transformation
of variables and statistical methods, such as intraclass correlation coef-
ﬁcient, coefﬁcient of variation, standard deviation, reliability coefﬁcient
and Bland–Altmann method) and the intervals between subsequent
tests (O'Brien et al., 1986; Ziegler et al., 1992; Gerritsen et al., 2003;
Lobnig et al., 2003; Kowalewski andUrban, 2004). Therefore, a proper as-
sessment of tests for the cardiovascular autonomic function requires a
standardization of the autonomic tests to avoid confounding factors that
could inﬂuence these measurements (Kowalewski and Urban, 2004).
Currently, seven parameters are used for the early detection of CAN
(Halsbeck et al., 2006) as follows: the three spectral analysis frequency
bands (VLF, LF and HF) and four tests proposed by Ewing (heart rate
response to the Valsalva maneuver, to deep breathing and to standing
and the blood pressure response to standing) (Ewing and Clarke,
1982). According to the consensus recommendations (American
Diabetes Association and American Academy of Neurology, 1988;
American Diabetes Association, 1992; Task Force of the European
Society of Cardiology and the North American Society of Pacing and
Electrophysiology, 1996; Vinik et al., 2003), a diagnosis of incipient
and deﬁnitive CAN is made when at least two and three of the seven
tests are abnormal with a speciﬁcity of 98% and 100%, respectively.
The present study was designed to investigate the day-to-day
variability of measurements of HRV with physiological stimuli in
young, healthy volunteers. In view of our results, we propose the
use of a statistical methodology to calculate sample size in longitudi-
nal clinical studies and studies testing drugs that takes into con-
sideration the reproducibility of the autonomic tests.
2. Material and methods
This study was performed on 67 healthy volunteers without any
underlying diseases (hospital employees and medical students).
None of the subjects were taking any medications, but all women
used oral contraceptives, and they were all judged to be healthy on
the basis of a physical examination and routine laboratory screening,
which revealed normal lipid and glycemic proﬁles. Each individual
was investigated on two different days in the morning (all of the
subjects were tested at 1-day interval).
The subjects were instructed to refrain from drinking alcohol- or
caffeine-containing beverages and to engage in smoking cessation
for a minimum of 8 h prior to testing and to refrain from strenuous
exercise for at least 24 h preceding the examination. The exclusion
criteria were fever in the last two days, emotional distress on the
day before the autonomic tests and arrhythmias.
Autonomic tests were performed in the morning. Subjects were
instructed to assume the supine position in a metabolic unit with a
controlled temperature (23 °C) after an overnight fast or at least 2 h
after a light meal (containing a total of 300 Kcal) standardized by a
dietitian.
After 10 min of rest in the supine position with the head elevated
45°, an electrocardiogram (EKG) was recorded during 5 min ofspontaneous breathing using a computer software (VNS-Rhythm/
Software Poly-Spectrum analysis). The EKG was analyzed by a math-
ematical algorithm (fast Fourier transform) and expressed in a diagram
of oscillation amplitude (heart rate variations per second) versus fre-
quency (hertz), that providing a simultaneous study of the heart rate.
The 5 min EKG recording was controlled by the operator in order to
maintain control breathing at 15 breaths/min and the subjects were
instructed to avoid irregular or deep breathing.
From 150 RR intervals that were free of artifacts, the computer cal-
culated the mean RR intervals (RRNN), the standard deviation of RR
intervals (SDNN), the coefﬁcient of variation (CV) (the standard devia-
tion of the distribution of RR intervals dividedby themean) and the root
mean squared of successive RR interval differences (RMSSD).
The total spectral amplitude of HRV was composed of the three
frequency bands of spectral analysis, which reﬂect the relative impact
of the sympathetic and parasympathetic modulation on the HRV
(Vinik and Ziegler, 2007). The VLF component (0.01 to 0.04 Hz) is
related to ﬂuctuations in the vasomotor tonus that is linked to ther-
moregulation and sweating (sympathetic control). The LF component
(0.04 to 0.15 Hz) is associated with the baroreﬂex (sympathetic
control with vagal modulation), and the HF component (0.15 to 0.5 Hz)
is related to sinus arrhythmia (parasympathetic control) (Vinik and
Ziegler, 2007).
The cardiovascular reﬂex tests (deep breathing test, Valsalva
maneuver, orthostatic test and hypotension orthostatic test) were also
performed. After each test, a resting period of 1 min was scheduled to
prevent inﬂuences by the previous tests.
The deep breathing test was performed 3 times. The subjects were
instructed to start the test with a deep and slow inspiration to the
maximum total lung capacity for 5 s, which was followed by a forced
expiration down to the residual volume for 5 s. The time to alternate
the respiratory cycle was signaled directly to the patient by the opera-
tor. The expiration:inspiration ratio (E:I ratio) was determined by the
ratio between the longest and shortest RR intervals obtained during
the expiration and inspiration cycles, respectively, and the highest E:I
ratio was considered (Spallone et al., 2011).
The Valsalva maneuver was performed 2 times and the subjects
were invited to blow with an open glottis into a mouthpiece connected
to a manometer and to maintain a constant expiratory effort equivalent
to an intraoral pressure of 40 mm Hg for 15 s. This test induces a phys-
iological tachycardia, which persists for a maximum of approximately
14 s. After this period, the expiratory straining was suddenly released,
and the subject should breathe regularly and remain silent andmotion-
less until the end of the test, when the physiological bradycardia was
observed. The Valsalva ratio was determined by the ratio between the
longest and shortest RR intervals (Ziegler et al., 1992; Rolim et al., 2008).
To perform the orthostatic test, the subjectswere invited to stand up
quickly but remain relaxed with their arms at rest alongside the body
and without speaking or moving until the end of the test (180 s after
standing up). The 30:15 or maximum:minimum (max:min) ratio was
determined by the ratio between the longest (maximum bradycardia
at approximately the 30th beat) and shortest (maximum tachycardia
at approximately the 15th beat) RR interval. During the orthostatic
test, the blood pressure was measured at baseline and after 3 min of
standing. A drop in the systolic blood pressure (sBP) higher than or
equal to 20 mm Hg was considered abnormal, and a drop in sBP
between 10 and 19 mm Hg was considered borderline (Rolim et al.,
2008; Spallone et al., 2011).
The study was approved by the local ethics committee, and the
participants gave written informed consent.
3. Data and statistical analysis
Analysis of the day-to-day variability was carried out using the
limits of agreement due to its straightforward interpretation and
using the within-subject standard deviation (WSSD), which is easy
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and was not present in the data. The WSSD was calculated as the
standard error of the mean of the variances obtained between days
1 and 2 for each subject and given by WSSD ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXn
i¼1
Xd
j¼1
xij−xj
 2
n
vuuuut
,
where n is the sample size and d is the number of measurements
obtained for each subject. The WSSD was used in the calculations of
the sample sizes.
The signiﬁcance of themean error between day 1 and day 2was cal-
culated using the t-test for dependent samples (paired t-tests), which
was adjusted to the multiple comparisons by the Sidák method.
Considering that there was a correlation between the error (inter-
day variability) and the magnitude of the measurements, the data
from spectral analysis (VLF, HF and LF) were logarithm transformed
for the calculations of the limits of agreement, according to Altman
and Bland, but the data from de minimum difference expected
according to sample size are presented as ms2.
The sample sizes were calculated for longitudinal studies, where the
size of each group is given by n ¼ 2⋅ zα
2
þ z1−β
 2
⋅ WSSD
MDE
 2
, with
MDE indicating the minimum difference expected between measures.
Using α = 0.05 (zα/2 = 1.96) and β = 0.20 (z1 − β = 0.84), we can
simplify the formula to n ¼ 16⋅ WSSD
MDE
 2
. We also calculated the mini-
mum statistically signiﬁcant differences according to the sample size of
hypothetical study populations.
An assessment of the reproducibility of the HRVmeasurements was
realized between the two different days using the Bland–Altman analy-
sis method. The Bland–Altman method calculates the mean difference
between two measurement methods performed on repeat occasions
and 95% limits of agreement as the difference of the means [1.96 stan-
dard deviation (SD)]. It is expected that the 95% limits include 95% of
the differences between the two measurement methods (Bland and
Altman, 1986, 1999). Random errors were assessed by both the limits
of agreement and WSSD.
To compare the tests studied and to determine which is the most
stable and adequate to use, we calculated a global mean (the mean of
all individual values in days 1 and 2 for the same test) and divided the
WSSD by this value, as a type of coefﬁcient of variation. Tests with a
smaller ratio between the WSSD and global mean would be the most
stable and the best choice.4. Results
The clinical and demographic data for the study population are
shown in Table 1.Table 1
Demographic data of the studied population.
Variable
N 67
Age, years 27 (19–39)
Gender, female (%) 45 (67.2)
Ethnicity, Caucasian (%) 64 (95.5)
Weight (kg) 66.2 ± 13.4
Height (cm) 167.6 ± 7.6
BMI (kg/m2) 23.4 ± 3.5
Smokers, n (%) 64 (95.5)
sBP (mm Hg) 113.6 ± 12.6
dBP (mm Hg) 71.6 ± 8.13
The data are presented as counts (percentage), means ± SD or medians
(minimum/maximum). BMI, body mass index; sBP, systolic blood pressure; dBP,
diastolic blood pressure.The means and SD for each parameter are presented in Table 2.
There were no signiﬁcant intra-subject differences between the base-
linemeasurements on each of the study days. A signiﬁcant p-value indi-
cates a systematic error between days. These results indicate that there
was no systematic error between the two days.
Table 3 shows the limits of agreement in the day-to-day measure-
ments of HRV using VNS-Rhythm. Using the criteria of the smaller
ratio WSSD/global mean, the most reliable parameters were the
Valsalva ratio, E:I ratio, max:min ratio and RRNN. A higher random
error was found for the decrease in sBP, LF, RMSSD and CV.
The results of our study showed no difference between HF (3 ± 0.4
vs 3.1 ± 0.3; p = 0.112) and VLF (3.1 ± 0.3 vs 3.2 ± 0.3; p = 0.101),
but lower levels of LF (3.1 ± 0.3 vs 3.3 ± 0.4; p = 0.026) in female
when compared to male sex, respectively.
The sample size estimates using the minimum differences, which
were expected to be statistically signiﬁcant for the different autonomic
measurement techniques in longitudinal studies using HRV tests, are
presented in Table 4. Table 4 presents the minimum difference to be
considered statistically signiﬁcant using various sample sizes, according
to the calculated WSSD. The E:I ratio, Valsalva ratio and max:min ratio
required the smallest sample size, and the decrease in sBP, VLF, LF or
HF required a much larger sample size due to the large random error.5. Discussion
Previous studies showed that the reproducibility of data from
normal subjects demonstrates coefﬁcients of variation of 6–8.9% for
the E:I ratio, 8–15.4% for the Valsalva ratio and 5.3–9% for the max:
min ratio (Spallone et al., 2011). Our study showed that there is good
reproducibility of the three tests proposed by Ewing, 11%, 18.6% and
14.1% for the E:I ratio, the Valsalva ratio and the max:min ratio, respec-
tively, and for parameters obtained by spectral analyses, RRNN (6.4%)
and SDNN (24.5%), which is in agreement with the literature data.
The results of this study showed that there were large limits of
agreement in the day-to-day measurements of the E:I ratio, the
max:min ratio, the Valsalva ratio and the CV, and there were important
random errors in the measurements of the HF, VLF and LF components
of spectral analysis and a decrease in the SBP after 3 min of standing in
the healthy subjects. Moreover, we did not detect a systematic error in
the measurements, as evidenced by the absence of statistically signiﬁ-
cant differences between the values of the HRVmeasurements between
days 1 and 2.
Previous studies have shown reduced RR variation related to female
gender (Vinik and Ziegler, 2007). It is well known that the data from
spectral analysis (VLF, HF and LF) are affected by sex, and the femalesTable 2
Parameters of cardiovascular autonomic function assessed during the 2 visits.
Parameter Day 1 Day 2 p value
RRNN (ms) 863.2 (118.68) 878.9 (106.26) 0.106
SDNN (ms) 64.2 (28.04) 65.8 (27.67) 0.573
RMSSD (ms) 51.7 (32.38) 85.1 (229.52) 0.237
CV (%) 7.4 (2.55) 16.9 (77.93) 0.320
VLF (ms2) 1951 (1852.44) 1630.9 (1098.76) 0.140
LF (ms2) 1730.6 (2050.36) 2145.7 (3667.67) 0.331
HF (ms2) 1466.1 (1904.22) 1543.2 (1654.73) 0.718
Decrease in SBP (mm Hg) −1.7 (8.8) −1.9 (8.02) 0.882
E:I ratio 1.52 (0.27) 1.51 (0.31) 0.789
Valsalva ratio 1.96 (0.56) 1.91 (0.54) 0.417
Max:min ratio 1.51 (0.61) 1.49 (0.59) 0.501
Values are presented as the mean (standard deviation). RRNN (mean RR intervals);
SDNN (standard deviation of all normal to normal RR intervals); CV (coefﬁcient of
variation); RMSSD VLF (very low frequency); LF (low frequency); HF (high frequency);
E:I ratio (expiration to inspiration ratio); Valsalva ratio;Max:min ratio (maximum tomin-
imum ratio); SBP (systolic blood pressure).
Table 3
Assessment of the limits of agreement in the day-to-day measurements of the heart
rate variability.
Parameter ME (IL/SL) WSSD WSSD/GM
ratio (%)
RRNN (ms) −15.7 (−174.55/143.14) 56.12 6.4
SDNN (ms) −1.6 (−47.43/44.3) 15.92 24.5
RMSSD (ms) −33.4 (−497.65/430.91) 162.52 237.7
CV (%) −9.6 (−167.91/148.76) 55.26 455.1
VLF (ms2) 0.02 (−1.64/1.69) 0.578 8.0
LF (ms2) −0.2 (−1.68/1.36) 0.538 7.5
HF (ms2) −0.2 (−1.8/1.48) 0.579 8.4
Decrease in SBP (mm Hg) 0.2 (−19.7/20.06) 6.89 380.5
E:I ratio 0 (−0.47/0.49) 0.17 11.0
Valsalva ratio 0.1 (−0.98/1.08) 0.36 18.6
Max:min ratio 0 (−0.58/0.63) 0.21 14.1
RRNN (meanRR intervals); SDNN (standard deviation of all normal to normal RR intervals);
CV (coefﬁcient of variation); RMSSD (the root mean squared of successive RR intervals dif-
ferences); VLF (very low frequency); LF (low frequency); HF (high frequency); E:I ratio (ex-
piration to inspiration ratio); Valsalva ratio; Max:min ratio (maximum to minimum ratio);
SBP (systolic bloodpressure);WSSD (within-subject standard deviation);GM, globalmean;
WWSD/GM Ratio (ratio between the within-subject standard deviation and global mean
values); ME (mean error between days); IL/SL (inferior and superior limits of agreement
(95%)).
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Our study only demonstrates statistical difference in the LF band of
spectral analysis which was lower in females when compared to
males. This could be explained by the asymmetry of the study popula-
tion (67% female sex). The minimum differences expected to be statis-
tically signiﬁcant according to the sample size for the different tests
showed that the E:I ratio, the Valsalva ratio, the max:min ratio, the
SDNN and the CV were much more adequate than the measurements
obtained by the spectral analysis (VLF, LF, HF, RRNN and RMSSD).
There are few studies showing the reproducibility of themeasurements
of HRVby spectral analysis.We found that sample sizes of approximately
50 and 25 subjects respectively are necessary to detect changes of
approximately 6.6% and 9.3% in RRNN; 13.9% and 20% in SDNN; 134.5%
and 190% in RMSSD; 255% and 363% in CV; 6.7% and 6.7% in the E:I
ratio; 10.3% and 15.4% in the Valsalva ratio; 6.7% and 13.3% in the max:
min ratio; 71.6% and 101.2% in LH; 39.5% and 56% in VLF; 46% and 65%
in HF; and a 222.2% and 333.3% decrease in sBP.
Despite the high prevalence and the clinical and prognostic impli-
cations, CAN is still under-diagnosed. The methodology used for the
diagnosis of CAN varies greatly between studies. Differences existTable 4
Estimates of the minimum differences expected between 2 days to be statistically sig-
niﬁcant using different sample sizes.
Parameter
Sample size
50 25 20 10
RRNN (ms) 32 45 50 71
SDNN (ms) 9 13 14 20
RMSSD (ms) 92 130 145 206
CV (%) 31 44 49 70
VLF (ms2) 1344 1901 2125 3005
LF (ms2) 1238 1751 1958 2769
HF (ms2) 995 1407 1573 2224
Decrease in SBP (mm Hg) 4 6 6 9
E:I ratio 0.1 0.1 0.1 0.2
Valsalva ratio 0.2 0.3 0.3 0.5
Max:min ratio 0.1 0.2 0.2 0.3
RRNN (meanRR intervals); SDNN (standard deviation of all normal to normal RR intervals);
CV (coefﬁcient of variation); RMSSD (the root mean squared of successive RR intervals dif-
ferences); VLF (very low frequency); LF (low frequency); HF (high frequency); E:I ratio (ex-
piration to inspiration ratio); Valsalva ratio; Max:min ratio (maximum to minimum ratio);
SBP (systolic blood pressure).not only in the types of ANS function tests that are used (conventional
tests or computerized HRV analysis) but also in the minimal diagnostic
criteria for CAN (one or two tests or more), reference values, subject
sample, duration of the HRV analysis (short-term assessment of 5 min
or long-term assessment of 24 h), the subject's body position (sitting,
lying or standing), breathing control (free breathing versus controlled
breathing), selection of HRV indices (time domain or frequency domain
variables) and the statistical procedures used (Ziegler, 1994).
The majority of the studies that evaluated the reproducibility of
the HRV parameters used to assess the autonomic nervous system
were performed in healthy subjects (O'Brien et al., 1986; Ziegler
et al., 1992; Gerritsen et al., 2003; Lobnig et al., 2003; Kowalewski and
Urban, 2004). These studies differ in some aspects including the
length of fasting, time to retest, variables analyzed, methodology
and the statistical method used to evaluate the reproducibility,
which make the interpretation of the results and the comparison
between studies difﬁcult (O'Brien et al., 1986; Ziegler et al., 1992;
Gerritsen et al., 2003; Lobnig et al., 2003; Kowalewski and Urban,
2004).
It has been demonstrated that a combination of autonomic function
tests based on standard, spectral and vector analyses is relatively more
sensitive in detecting CAN than the traditional test battery proposed by
Ewing and Clarke (Ziegler, 1994). Furthermore, the detection of HRV by
a spectral analysis has the advantage of being carried out at rest and
does not require the active cooperation of the patient (Ziegler, 1994).
Although it is low cost, non-invasive, operator independent, easy
to perform and does not require the active cooperation of the patient,
the HRV obtained by spectral analyses (LF, VLF and HF) demonstrates
poor reproducibility in our study. Thus, the random error inherent in
measurements of spectral analysis should be thoroughly evaluated
when calculating the statistical power and sample sizes in longitudinal
studies that evaluate the cardiovascular autonomic function as a diag-
nostic of CAN.
Based on reproducibility data some experts do not recommend the
use of spectral analysis parameters for CAN diagnosis. The consensus
statement of the 1992 San Antonio conference on diabetic neuropathy
(American Diabetes Association and American Academy of Neurology,
1988) recommended using the battery of three cardiovascular reﬂex
tests that was proposed by Ewing and Clarke for diagnosing CAN, as
follows: the heart rate variation during deep breathing, the Valsalva
maneuver and orthostatism and the tests of blood pressure variation
during orthostatism (orthostatic hypotension) (Ziegler, 1994; Agelink
et al., 2001; Spallone et al., 2011).
In 2009, The Toronto Diabetic Neuropathy Expert Group provided
updates on diagnostic criteria for CAN. The experts suggested to per-
form standardized tests to assess cardiac parasympathetic function
(HR response to deep breathing, Valsalva and postural change) and
cardiac sympathetic function (BP response to Valsalva and postural
change) (Tesfaye et al., 2010). The experts concluded that diagnostic
criteria and staging of CAN are still a matter of debate but concluded
that the presence of two abnormal tests is required for a conﬁrmed
diagnosis of CAN and the addition of orthostatic hypotension con-
ferred severity to CAN diagnosis (Tesfaye et al., 2010).
When calculating the reproducibility of methods, it is important
to differentiate the intervention effects from measurement errors.
Measurement errors can be divided into the following two main
components: random and systematic errors. Random error is always
present in a measurement and is not related to the clinical intervention
because it is caused by inherently unpredictable ﬂuctuations in the
readings by the measuring equipment. In contrast, systematic errors
are predictable biases in the measurement that are not related to the
clinical intervention and that can be attributed to the experimental
protocol. Therefore, they can be observed in all of the subjects, and
they interfere directly with the accuracy of the measurement. In this
situation, the effect of a clinical intervention must be greater than
the systematic error for it to be detected and considered a real effect,
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the sample size required to achieve a sufﬁcient power to detect the
effects of a clinical intervention (Tibiriçá et al., 2011).
In the literature, there is no agreement on the period of fasting
required before the tests are performed. According to Dyck and
Thomas (1999) and Halsbeck et al. (2006), a minimum of 8 h of fasting
should occur before the autonomic tests because the post-prandial
release of insulin that is stimulated by a meal could stimulate an
increased release of norepinephrine and could possibly inﬂuence the
heart rate and blood pressure.
Spallone et al. (2011) suggests performing the tests when fasting
or at least 2 h after a light meal, which was carried out in the present
study. In the Hoorn Study (Gerritsen et al., 2000), the participants
were asked to refrain from smoking and drinking coffee for 2 h prior
to the assessment of cardiovascular autonomic function, and the tests
took place at least 1 h after a light meal.
The recommendations of the San Antonio Consensus Panel are as
follows: each center needs to establish reference values based on
the population studied and stratiﬁed by age because a pronounced
age dependency of heart variability parameters has been recognized;
a battery of quantitative tests must be used; independent tests of
both parasympathetic and sympathetic functions must be performed;
and more than one test should be abnormal to establish the presence
of CAN (American Diabetes Association and American Academy of
Neurology, 1988; Dyck and Thomas, 1999; Vinik et al., 2003).
The main strength of the present study is that this is the ﬁrst study
conducted with the purpose of analyzing the reproducibility of the
HRV parameters for assessing the autonomic nervous system in the
Brazilian population. According to our study, we determined the min-
imum expected differences in the HRV variables based on the repro-
ducibility of the data, which enables the calculation sample size for
longitudinal clinical and testing drug studies.
Some limitations of our study include the lack of using a synchro-
nized ventilation cycle by an external trigger because both HF and LF
domains are inﬂuenced by ﬂuctuations in the vagal modulation during
respiration, the gender asymmetry and the small sample evaluated
(Lobnig et al., 2003).
6. Conclusion
This study showed that short-term spectral analysis of HRV (VLF, HF
and LF) despite being a practical tool for screening CAN, demonstrated
poor reproducibility. The evaluation of cardiovascular autonomic
function, as determined by the tests proposed by Ewing (Valsalva
ratio, deep breathing ratio and maximum:minimum ratio during
orthostatism) in addition to some time-domain indices of HRV (CV,
RRNN and SDNN), appears to provide good levels of reproducibility,
which are similar to those obtained in previous studies.
According to our study, some tests that assess the HRV showed an
adequate reproducibility. In view of our results, we propose the use of
a statistical methodology to calculate the sample size in longitudinal
clinical studies and studies testing drugs that takes into consideration
the reproducibility of the autonomic tests.
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